Circumcision status and incident herpes simplex virus type 2 infection, genital ulcer disease, and HIV infection
- PMID: 22382150
- PMCID: PMC3668787
- DOI: 10.1097/QAD.0b013e328352d116
Circumcision status and incident herpes simplex virus type 2 infection, genital ulcer disease, and HIV infection
Abstract
Objective: We assessed the protective effect of medical male circumcision (MMC) against HIV, herpes simplex virus type 2 (HSV-2), and genital ulcer disease (GUD) incidence.
Design: Two thousand, seven hundred and eighty-seven men aged 18-24 years living in Kisumu, Kenya were randomly assigned to circumcision (n=1391) or delayed circumcision (n=1393) and assessed by HIV and HSV-2 testing and medical examinations during follow-ups at 1, 3, 6, 12, 18, and 24 months.
Methods: Cox regression estimated the risk ratio of each outcome (incident HIV, GUD, HSV-2) for circumcision status and multivariable models estimated HIV risk associated with HSV-2, GUD, and circumcision status as time-varying covariates.
Results: HIV incidence was 1.42 per 100 person-years. Circumcision was 62% protective against HIV [risk ratio=0.38; 95% confidence interval (CI) 0.22-0.67] and did not change when controlling for HSV-2 and GUD (risk ratio=0.39; 95% CI 0.23-0.69). GUD incidence was halved among circumcised men (risk ratio=0.52; 95% CI 0.37-0.73). HSV-2 incidence did not differ by circumcision status (risk ratio=0.94; 95% CI 0.70-1.25). In the multivariable model, HIV seroconversions were tripled (risk ratio=3.44; 95% CI 1.52-7.80) among men with incident HSV-2 and seven times greater (risk ratio=6.98; 95% CI 3.50-13.9) for men with GUD.
Conclusion: Contrary to findings from the South African and Ugandan trials, the protective effect of MMC against HIV was independent of GUD and HSV-2, and MMC had no effect on HSV-2 incidence. Determining the causes of GUD is necessary to reduce associated HIV risk and to understand how circumcision confers protection against GUD and HIV.
Conflict of interest statement
There are no conflicts of interest.
Comment in
-
Herpes simplex virus type-2 assay specificity and male circumcision to reduce herpes simplex virus type-2 acquisition.AIDS. 2013 Jan 2;27(1):147-9. doi: 10.1097/QAD.0b013e32835aa181. AIDS. 2013. PMID: 23221430 Free PMC article.
-
Response to 'Herpes simplex virus type-2 (HSV-2) assay specificity and male circumcision to reduce HSV-2 acquisition.AIDS. 2013 Jan 2;27(1):149-50. doi: 10.1097/QAD.0b013e328358cc92. AIDS. 2013. PMID: 23221431 No abstract available.
References
-
- Bailey RC, Moses S, Parker CB, Agot K, Maclean I, Krieger JN, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet. 2007;369:643–656. - PubMed
-
- Gray RH, Kigozi G, Serwadda D, Makumbi F, Watya S, Nalugoda F, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet. 2007;369:657–666. - PubMed
-
- McCoombe SG, Short RV. Potential HIV-1 target cells in the human penis. AIDS. 2006;20:1491–1495. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
